¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"drug intoxication"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • gateway drug
    Åë·Î¼ö´Ü¾à¹°, ½À°üÇü¼º¾à¹°
  • generic drug name
    ÀϹݾà¸í
  • hallucinogenic drug
    ȯ°¢Á¦
  • idiosyncratic drug response
    ƯÀ̾๰¹ÝÀÀ
  • inotropic drug
    ¼öÃàÃËÁø¾à
  • mucosal protective drug
    Á¡¸·º¸È£Á¦
  • multiple drug resistance
    ´Ù¾àÁ¦³»¼º, ¿©·¯¾àÀúÇ×
  • narcotic drug
    ¸¶¾à
  • new drug application
    ½Å¾àÇã°¡½Åû
  • nonsteroidal antiinflammatory drug
    ºñ½ºÅ×·ÎÀ̵å¼Ò¿°Á¦, ºñ½ºÅ×·ÎÀ̵åÇ׿°ÁõÁ¦
  • orphan drug
    Èñ±Í¾à
  • prescription drug
    󹿾à
  • prokinetic drug
    À§Àå¿îµ¿ÃËÁøÁ¦
  • psychedelic drug
    ȯ°¢Á¦
  • psychoactive drug
    Á¤½ÅÀÛ¿ëÁ¦
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • drug-induced jaundice
    ¾à¹°À¯¹ßȲ´Þ
  • drug-induced purpura
    ¾à¹°À¯¹ßÀÚ»ö¹Ý
  • drug-induced retinopathy
    ¾àÀ¯¹ß¸Á¸·º´Áõ
  • drug-induced rhinitis
    ¾à¹°À¯¹ßÄÚ¿°, ¾à¹°À¯¹ßºñ¿°
  • ganglionic blocking drug
    ½Å°æÀýÂ÷´Ü¾àÁ¦
  • hallucinogenic drug
    (¢¡hallucinogen) ȯ°¢Á¦
  • hematinic drug
    Á¶Ç÷Á¦
  • hematological drug
    Ç÷¾×ÀÛ¿ë¾à
  • inotropic drug
    ¼öÃàÃËÁø¾à
  • mucosal protective drug
    Á¡¸·º¸È£Á¦
  • narcotic drug
    ¸¶¾à
  • nonsteroidal antiinflammatory drug
    ºñ½ºÅ×·ÎÀ̵å¼Ò¿°Á¦, ºñ½ºÅ×·ÎÀ̵åÇ׿°ÁõÁ¦
  • orphan drug
    Èñ±ÍÀǾàǰ
  • parasympathetic drug
    ºÎ±³°¨½Å°æ¾à
  • parasympathomimetic drug
    ºÎ±³°¨ÈïºÐÁ¦
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • chemotherapeutic drug monitoring
    È­Çпä¹ý¾àÁ¦°¨½Ã
  • cognitive-acting drug(=enhancer)
    ÀÎÁö±â´ÉȰ¼ºÁ¦(ìãò±Ñ¦ÒöüÀàõð¥)
  • common drug =c. medicament
    º¸Åë¾à(ÜÅ÷×å·).
  • competitive drug
    °æÇÕ¾à(Ìæùêå·).
  • crude drug
    »ý¾à(ßæå·), Á¶¾à.
  • cutaneous drug reaction
    ÇǺξàÁø
  • cytotoxic drug
    ¼¼Æ÷µ¶¼º¾à¹°.
  • cytotoxic drug
    Ç÷¾×Æ÷µ¶¼ºÁ¦<¾à>, ¼¼Æ÷µ¶¼º ¾à¹°.
  • dependence, drug
    ¾àÁ¦ÀÇÁ¸¼º
  • depolarizing neuromuscular blocking drug
    Å»ºÐ±Ø¼º ½Å°æ±ÙºÀ¼â¾à¹°.
  • diagnostic agent =d.drug
    Áø´Ü(»ó)ÀÇ(¿ë)¾à(¡­éÄå·).
  • drug
    ¾à(å·), ¾à¹°, ¾àÁ¦.
  • drug
    ¾à¹°(å·Úª)
  • drug (induced) allergy
    ¾à¹°(À¯¹ß) ¾Ë·¹¸£±â.
  • drug abstinence
    ¾à¹°±Ý´Ü, ±Ý´Ü(Ð×Ó¨).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 7
AL absolute latency; acinar lumen; acute leukemia; adaptation level; albumin; alcoholism [and other dru...
AMA-DE American Medical Association Drug Evaluation
AMSAODD American Medical Society on Alcoholism and Other Drug Dependencies
ANDA Abbreviated New Drug Application
AODP alcohol and other drug problems
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 7
IVDU IV drug users
IDU Injecting drug use
IDU Injecting drug users
IDU Injection drug use
IDU Injection drug users
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • immunosuppressive drug
    ¸é¿ª ¾ïÁ¦Á¦
    »ýüÀÇ ¸é¿ª ¹ÝÀÀÀ» ¾ïÁ¦ÇÏ´Â ¾àÁ¦. »ýü ³»¿¡¼­ ¸é¿ª ¹ÝÀÀÀ¸·Î Á¶Á÷ÀÌ Àå¾Ö¸¦ ¹Þ¾Æ º´ÀÌ ÀϾ´Â °æ¿ì°¡ ÀÖ´Ù. ƯÈ÷, Ç׿ø ¹°ÁúÀÌ ÀÚ±âÀÇ Ã¼¼ººÐÀÏ °æ¿ì¿¡´Â ÀÚ°¡ ¸é¿ª ÁúȯÀ̶ó°í ÇÑ´Ù. ÀÚ°¡ ¸é¿ª Áúȯ¿¡¼­´Â ´ë°³ÀÇ °æ¿ì, Á¦ 1¼±ÅÃÁ¦·Î¼­ ºÎ½Å ÇÇÁú È£¸£¸óÀÌ ¾²À̸ç, À̰Ϳ¡ ÀúÇ×À» ³ªÅ¸³»´Â µî ÇѰ谡 ÀÖÀ» °æ¿ì°¡ ÀÖ´Ù. ÀÌ·¯ÇÑ ¶§ ¸é¿ª ¹ÝÀÀÀ¸·Î ÀÎÇÑ º´Å¿¡ ´ëÇÏ¿©, À̸¦ ¾ïÁ¦Çϰí Ä¡·áÇϱâ À§ÇÏ¿© ¸é¿ª ¾ïÁ¦Á¦°¡ »ç¿ëµÈ´Ù. ¶Ç Àå±â ÀÌ½Ä ¶§ °ÅºÎ ¹ÝÀÀÀ» ¾ïÁ¦Çϱâ À§Çؼ­µµ »ç¿ëµÈ´Ù. ¸é¿ª¾ïÁ¦¿¡´Â ±× ¹ÝÀÀ¸¸À» ¾ïÁ¦Çϴ ƯÀÌÇÑ °Í°ú ±×·¸Áö ¾ÊÀº °ÍÀÌ ÀÖÀ¸¸ç, ÀÌ·ÐÀûÀ¸·Î´Â ƯÀÌÇÑ ÂÊÀÇ ÀÛ¿ëÀÌ ¶Ù¾î³ª¾ß ÇϰÚÁö¸¸, ÀÓ»óÀûÀ¸·Î ¾²ÀÌ´Â °ÍÀº °ÅÀÇ ºñƯÀÌÀû ¸é¿ª ¾ïÁ¦Á¦ÀÌ´Ù. ºñƯÀÌÀû ¸é¿ª ¾ïÁ¦Á¦¿¡´Â »çÀÌŬ·ÎÆ÷½ºÆÄ¹Ìµå, ´ÏÆ®·Î°Õ¸¶½ºÅ¸µå µîÀÇ ¾ËųȭÁ¦, 6-¸Þ¸£Ä°ÅäǪ¸°, ¾ÆÀÚÆ¼¿ÀǪ¸°, ½ÃÅä½Å¾Æ¶óºñ³ë½Ãµå µî°ú °°Àº ´ë»ç ±æÇ×Á¦, ¹ÌÅ丶À̽ŠC, ¾ÇƼ³ë¸¶À̽ŠD µîÀÇ Ç×»ý ¹°Áú, ºÎ½Å ÇÇÁú ½ºÅ×·ÎÀ̵åÁ¦, ºó¾ËÄ®·ÎÀ̵åÁ¦, Ç׸²ÇÁ±¸ Ç÷û µîÀÇ Ç×ü µî ¿©·¯ Á¾·ùÀÇ ¾àÁ¦°¡ ÀÖ´Ù. ÀÌµé ¸é¿ª ¾ïÁ¦Á¦´Â Ç׿ø Àڱؿ¡¼­ Ç×ü »ý¼º±îÁö À̸£´Â µ¿¾È¿¡, ¸ÅÅ©·ÎÆÄÁö¿¡ ÀÇÇÑ Ç׿øÀÇ Å½½Ä, ¸²ÇÁ±¸¿¡ ÀÇÇÑ Ç׿ø ÀνÄ, ¼¼Æ÷ ºÐ¿­, T ¼¼Æ÷¿Í B ¼¼Æ÷ÀÇ ºÐ¿­, Ç×ü »ý¼º µî ¸î °¡Áö °úÁ¤À» ÀúÇØ½ÃÅ´À¸·Î½á ¸é¿ª¾ïÁ¦¸¦ ¾ß±â½ÃŲ´Ù. ´ëºÎºÐÀÌ Ç×Á¾¾ç Ȱ¼ºÀ» °¡Áö°í À־, DNA
  • individual drug
    °³°³ÀÎ ¾à¹°
  • Langmuir expression in drug-antibody binding
    ¾à¹°-Ç×ü °áÇÕ¿¡¼­ÀÇ ¶û¹¿¸£ Ç¥Çö
  • lichenoid drug reaction
    ż±¾ç ¾à¹° ¹ÝÀÀ
  • like drug
    ¸ð¸£ÇÉ À¯»ç ¾à¹°
  • long acting drug
    Áö¼Ó¼º ¾à
  • metabolic drug
    ´ë»ç ¾à¹°
  • misbranded drug
    ºÎÁ¤ Ç¥½Ã ¾àǰ
  • morphine like drug
    ¸ð¸£ÇÉ À¯»ç ¾à¹°
  • multiple drug misuse
    ¿©·¯ ¾à¹°ÀÇ ¿À¿ë
  • multiple drug resistance gene
    º¹ÇÕ ¾àÁ¦ ³»¼º À¯ÀüÀÚ
  • narcotic drug
    ¸¶¾à
    ¸ð¸£ÇÉ, ÄÚÄ«ÀÎ, ¾ÆÆí µî°ú ±× À¯µµÃ¼·Î¼­ ¹Ì·®À¸·Î °­·ÂÇÑ ÁøÅë ÀÛ¿ë°ú ¸¶Ãë ÀÛ¿ëÀ» Áö´Ï¸ç °è¼Ó »ç¿ëÇÏ¸é ½À°ü¼º°ú Ž´Ð¼ºÀÌ »ý±â°Ô ÇÏ´Â ¹°Áú. »ç¿ëÀ» Áß´ÜÇÏ¸é °Ý·ÄÇÑ ±Ý´Ü Áõ¼¼¸¦ ÀÏÀ¸ÄÑ ¸¶¾àÀ» »ç¿ëÇÏÁö ¾Ê°í´Â Á¤»óÀûÀÎ »ýȰÀ» ÇÒ ¼ö ¾ø°Ô µÇ¸ç, Á¾±¹¿¡ °¡¼­´Â À°Ã¼ÀûÀ¸·Î³ª Á¤½ÅÀûÀ¸·Î ÆóÀÎÀÌ µÇ°Ô ÇÏ´Â ¹°ÁúÀÌ´Ù. ÀÌ·± ¹°ÁúÀÌ ÀÇ·á ¹× ¿¬±¸ ÀÌ¿ÜÀÇ ¸ñÀû¿¡ ³²¿ëµÇ´Â À§ÇèÀ» ¹æÁöÇϱâ À§ÇÏ¿© Á¤ÇÑ ¹ý·ü»ó ¿ë¾î°¡ ¸¶¾àÀÌ´Ù. ¸¶¾àÀº ¨ç ¾Þ¼Ó¿¡¼­ äÃëÇÏ´Â ¾ÆÆí ¾ËÄ®·ÎÀ̵å°è ¸¶¾à
  • negative drug history
    À½¼º Åõ¾à º´·Â
  • neuroleptic drug
    ½Å°æ ÀÌ¿ÏÁ¦
  • new drug application
    ½Å¾à Çã°¡ ½Åû
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
drug resistance, neoplasm Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.
(12 Dec 1998)
drug resistant Unresponsive to the desired effects of drugs or other therapy for example: irradiation cytotoxic agents or hormones. Drug resistance of cells within tumours is probably the major cause of treatment failure.
(16 Dec 1997)
drug screening Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications.
(12 Dec 1998)
drug screening assays, antitumour Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumour growth parameters in laboratory animals.
(12 Dec 1998)
drug side effect An often undesirable effect that occurs in association with the use of a particular medication.
Examples of common drug side effects include: nausea, vomiting, sedation, dizziness, headache and weakness. Drug side effects that occur in 1% or more, of patients taking a particular medication are considered to be causally related to the use of that medication.
(27 Sep 1997)
drug tetanus Tonic spasms caused by strychnine or other tetanic.
Synonym: toxic tetanus.
(05 Mar 2000)
drug therapy, combination Drug therapy with two or more drugs given separately for a combined effect.
(12 Dec 1998)
drug therapy, computer-assisted Adjunctive computer programs in providing drug treatment to patients.
(12 Dec 1998)
drug, tocolytic A medication that can inhibit labour, slow down or halt the contractions of the uterus. Tocolytic agents are widely used today to treat premature labour and permit pregnancy to procede and so permit the foetus to gain in size and maturity before being born.
(12 Dec 1998)
drug tolerance Progressive diminution of the susceptibility of a human or animal to the effects of a drug, resulting from its continued administration. It should be differentiated from drug resistance wherein a human, animal, disease, or tissue fails to respond to the intended effectiveness of a chemical or drug.
(12 Dec 1998)
drug toxicity The systemic effects of a drug that are related to the overall level of the medication in the bloodstream. Drug toxicity may occur with overdosage of a medication, accumulation of the drug in the body over time or the inability of the patients body to eliminate the drug.
(27 Sep 1997)
drug utilization The utilization of drugs as reported in individual hospital studies, FDA studies, marketing, or consumption, etc. This includes drug stockpiling, and patient drug profiles.
(12 Dec 1998)
drug utilization review Formal programs for assessing drug prescription against some standard. Drug utilization review may consider clinical appropriateness, cost effectiveness, and, in some cases, outcomes. Review is usually retrospective, but some analysis may be done before drugs are dispensed (as in computer systems which advise physicians when prescriptions are entered). Drug utilization review is mandated for medicaid programs beginning in 1993.
(12 Dec 1998)
drug withdrawal A clinical syndrome of psychological, and, sometimes physical factors that result from the sustained use of a particular drug when the drug is abruptly withdrawn.
Symptoms are variable but may include anxiety, nervousness, irritability, sweating, nausea, vomiting, rapid heart rate, rapid breathing and seizures.
(27 Sep 1997)
dyskinesia, drug-induced Abnormal movements induced as an adverse reaction of drug therapy. One particular movement disorder is the "on-off" effect. Tardive dyskinesia differs from akathisia, drug-induced in the repetitive nature of the movements rather than being associated with anxiety, restlessness, and agitation found in akathisia.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 7
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 7
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 7
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 7
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 7
ÅëÇÕ°Ë»ö ¿Ï·á